Condition: Hepatopancreaticobiliary (HPB) Malignancy · Ovarian Cancer (OvCa) · Kidney Cancers · Sponsor: The Methodist Hospital Research Institute
In this 2-arm, non-randomized, phase II trial, the investigators will evaluate the efficacy and safety of comprehensive multimodal prehabilitation (CMMP) alone or in combination with planned neoadjuvant (NAT) in pre-frail/frail patients with probable/proven pancreaticobiliary, ovarian, kidney, or bladder cancer prior to elective major cancer surgery (EMCS).
This description comes directly from the study's public registry record.
Darrel Cleere, BSN,RN,CCRP · 713-441-6232 · dwcleere@houstonmethodist.org
Shondra Word · 713-441-5122 · sword@houstonmethodist.org
Always discuss trial participation with your own doctor first.
| Houston Methodist Neal Cancer Center | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07050771